Pancreatic cancer, more specifically its common aggressive form, pancreatic ductal adenocarcinoma, has very little therapeutic options.

Because of sparse evidence in literature, we tested nicotinamide (vitamine B3) as an add-on to a treatment with gemcitabine in mouse models of pancreatic cancer. This combination therapy was effective in reducing tumor growth and metastasis by activating anti-tumor immunity and by modulating the stroma.

The study warrants further exploring the potential of nicotinamide plus gemcitabine as immunotherapy in pancreatic cancer.

Read the full article here.